#6 - Merck & Company (NYSE:MRK)
Merck & Company (NYSE:MRK) is a best-in-breed pharmaceutical stock. However, the stock has been under-the-radar of some investors because it’s not part of the Covid-19 vaccine race. This was evident in the fact that MRK stock dropped 10% in 2020. Some of that is attributable to the company spinning off several of its business units, and the associated $6.5 billion in revenue, to a different company.
However, the company still has a strong performer in its oncology drug, Keytruda, which delivered a record $14 billion in revenue in 2020 and is on pace to do even better in 2021. Investors will certainly note that Keytruda has patent protection in the United States for another six years. And in the European Union and Japan the protections go even further.
Analysts have a consensus price target that gives MRK stock a 20% upside. The stock has paid out a dividend for the last 11 years.
About Merck & Co., Inc.
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Read More - Current Price
- $99.84
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 11 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $124.00 (24.2% Upside)
